Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells
- PMID: 20551068
- DOI: 10.1158/0008-5472.CAN-09-4716
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells
Erratum in
- Cancer Res. 2011 Apr 1;71(7):2803
Abstract
Poly(ADP-ribose) (PAR) polymerase 1 (PARP1) is activated by DNA single-strand breaks (SSB) or at stalled replication forks to facilitate DNA repair. Inhibitors of PARP efficiently kill breast, ovarian, or prostate tumors in patients carrying hereditary mutations in the homologous recombination (HR) genes BRCA1 or BRCA2 through synthetic lethality. Here, we surprisingly show that PARP1 is hyperactivated in replicating BRCA2-defective cells. PARP1 hyperactivation is explained by the defect in HR as shRNA depletion of RAD54, RAD52, BLM, WRN, and XRCC3 proteins, which we here show are all essential for efficient HR and also caused PARP hyperactivation and correlated with an increased sensitivity to PARP inhibitors. BRCA2-defective cells were not found to have increased levels of SSBs, and PAR polymers formed in HR-defective cells do not colocalize to replication protein A or gammaH2AX, excluding the possibility that PARP hyperactivity is due to increased SSB repair or PARP induced at damaged replication forks. Resistance to PARP inhibitors can occur through genetic reversion in the BRCA2 gene. Here, we report that PARP inhibitor-resistant BRCA2-mutant cells revert back to normal levels of PARP activity. We speculate that the reason for the sensitivity of HR-defective cells to PARP inhibitors is related to the hyperactivated PARP1 in these cells. Furthermore, the presence of PAR polymers can be used to identify HR-defective cells that are sensitive to PARP inhibitors, which may be potential biomarkers.
Copyright 2010 AACR.
Similar articles
-
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.Nature. 2005 Apr 14;434(7035):913-7. doi: 10.1038/nature03443. Nature. 2005. PMID: 15829966
-
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.Br J Radiol. 2008 Oct;81 Spec No 1:S6-11. doi: 10.1259/bjr/99111297. Br J Radiol. 2008. PMID: 18820000
-
Replication fork stability confers chemoresistance in BRCA-deficient cells.Nature. 2016 Jul 21;535(7612):382-7. doi: 10.1038/nature18325. Nature. 2016. PMID: 27443740 Free PMC article.
-
The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.Mol Oncol. 2011 Aug;5(4):387-93. doi: 10.1016/j.molonc.2011.07.001. Epub 2011 Jul 22. Mol Oncol. 2011. PMID: 21821475 Free PMC article. Review.
-
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15. Bull Cancer. 2015. PMID: 26384693 Review. French.
Cited by
-
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.J Clin Oncol. 2015 Apr 20;33(12):1397-406. doi: 10.1200/JCO.2014.58.8848. Epub 2015 Mar 16. J Clin Oncol. 2015. PMID: 25779564 Free PMC article. Review.
-
Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.PLoS One. 2012;7(12):e51563. doi: 10.1371/journal.pone.0051563. Epub 2012 Dec 12. PLoS One. 2012. PMID: 23251575 Free PMC article.
-
PARP inhibitors in the management of breast cancer: current data and future prospects.BMC Med. 2015 Aug 13;13:188. doi: 10.1186/s12916-015-0425-1. BMC Med. 2015. PMID: 26268938 Free PMC article. Review.
-
Poly(ADP-ribose) polymerase-1 and its ambiguous role in cellular life and death.Cell Stress. 2023 Jan 23;7(1):1-6. doi: 10.15698/cst2023.01.275. eCollection 2023 Jan. Cell Stress. 2023. PMID: 36743979 Free PMC article.
-
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.Front Mol Biosci. 2022 Dec 1;9:1073797. doi: 10.3389/fmolb.2022.1073797. eCollection 2022. Front Mol Biosci. 2022. PMID: 36533080 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous